Latest Biotech News

UK‑based DNA Electronics presented data advancing its LiDia‑SEQ cartridge sequencing platform as a rapid, automated diagnostic for bloodstream infections and cancer, targeting same‑day results...

Sofinnova Partners closed a €750 million (reported $750M) fund to support early‑stage therapeutics, and European investors launched additional sizable vehicles to replenish venture capital for...

Thermo Fisher Scientific opened its East Coast Advanced Therapies Collaboration Center in Philadelphia to support cell and gene therapy development, expanding its national network of ATxCC sites....

Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, securing Halda’s precision oncology pipeline led by the clinical-stage oral candidate HLD-0915. Halda’s lead...

The FDA cleared Arrowhead Pharmaceuticals’ RNA interference therapy Redemplo (plozasiran) for familial chylomicronemia syndrome, marking the company’s first commercial product and the second RNAi...

Roche reported positive Phase III results for its oral selective estrogen receptor degrader (SERD) giredestrant in the adjuvant setting for estrogen-receptor–positive, HER2-negative early breast...

Researchers published the most comprehensive physiological and multiomic dataset to date from a pig-to-human kidney transplant conducted in a brain-dead recipient, tracking the graft and host...

U.S. health officials under Health Secretary Robert F. Kennedy Jr. have discussed sweeping changes to vaccine policy, including discouraging adjuvants used to boost shot effectiveness and...

Roche agreed to a collaboration and licensing deal with Freenome worth potentially more than $200 million to commercialize Freenome’s blood-based cancer screening tests outside the U.S.; Roche...

Nvidia, Sheba Medical Center’s ARC Innovation and the Icahn School of Medicine at Mount Sinai launched a three‑year collaboration to develop a large language model (genomic Foundation Model, gFM)...

UK diagnostics firm DNA Electronics presented data supporting its LiDia‑SEQ rapid sequencing platform and said it plans commercialization in 2027, targeting same‑day infectious-disease and cancer...

Iambic closed a $100 million financing to accelerate AI drug‑discovery platforms (Enchant and NeuralPLexer) and move cancer candidates toward the clinic; investors include Abingworth and...

A JAMA Internal Medicine analysis found that federal funding cuts led to termination of 383 NIH‑funded clinical trials between late February and mid‑August, disrupting more than 74,000 enrolled...

U.S. health-policy proposals under the Trump administration and Health Secretary Robert F. Kennedy Jr. are prompting vaccine manufacturers to raise concerns about rapid, wide-ranging changes to...

Roche reported positive Phase 3 data for its oral selective estrogen receptor degrader (SERD) giredestrant in the adjuvant setting for ER-positive, HER2-negative early breast cancer. At a...

Zymeworks and Jazz Pharmaceuticals announced positive topline results from the Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab (Ziihera) in first-line HER2-positive gastroesophageal...

Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to gain the company's regulated induced proximity targeting chimera (RIPTAC) technology and lead candidate HLD-0915...

Merck agreed to acquire Cidara Therapeutics for $9.2 billion to secure CD388, a late-stage investigational long-acting, strain-agnostic antiviral designed to prevent symptomatic influenza in...

Roche and Freenome struck a multiyear collaboration that gives Roche exclusive rights to develop and commercialize kit-based versions of Freenome's blood-based cancer screening tests outside the...

Iambic closed an oversubscribed $100 million financing round to expand its AI platforms Enchant and NeuralPLexer and advance cancer drug candidates. The company says Enchant predicts clinical and...